Short Interest in Intelligent Bio Solutions Inc. (NASDAQ:INBS) Increases By 147.3%

Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 90,000 shares, an increase of 147.3% from the May 31st total of 36,400 shares. Currently, 2.9% of the shares of the company are sold short. Based on an average trading volume of 61,400 shares, the days-to-cover ratio is presently 1.5 days.

Intelligent Bio Solutions Stock Performance

Shares of INBS opened at $1.92 on Friday. Intelligent Bio Solutions has a 1 year low of $1.76 and a 1 year high of $39.48. The company has a market cap of $5.99 million, a price-to-earnings ratio of -0.05 and a beta of 4.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.87 and a current ratio of 2.02. The firm has a fifty day moving average of $2.29 and a 200-day moving average of $3.39.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter. The company had revenue of $0.82 million during the quarter. Intelligent Bio Solutions had a negative return on equity of 210.36% and a negative net margin of 354.86%. As a group, equities analysts anticipate that Intelligent Bio Solutions will post -3.67 earnings per share for the current year.

Institutional Investors Weigh In On Intelligent Bio Solutions

An institutional investor recently bought a new position in Intelligent Bio Solutions stock. CVI Holdings LLC acquired a new position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 108,250 shares of the company’s stock, valued at approximately $457,000. Intelligent Bio Solutions accounts for approximately 0.4% of CVI Holdings LLC’s holdings, making the stock its 27th largest holding. CVI Holdings LLC owned about 3.81% of Intelligent Bio Solutions at the end of the most recent reporting period. Institutional investors and hedge funds own 32.97% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.